FIELD: medicine, laboratory diagnostics.
SUBSTANCE: the present innovation deals with detecting the concentration of antibodies to neurospecific enolase (NSE) and gliofibrillo-acid protein (GFAP) in blood serum of pregnant women. The development of gestosis should be predicted at the level of anti-NSE-antibodies being above 0.6 mcg/ml or anti-GFAP-antibodies being above 0.9 mcg/ml. The innovation provides high information value and specificity of the method suggested to predict the development of gestosis.
EFFECT: higher efficiency.
3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE DEVELOPMENT OF GESTOSIS | 2005 |
|
RU2304783C1 |
| METHOD FOR PREDICTION OF ONSET OF GESTOSIS IN PREGNANT WOMEN | 2011 |
|
RU2478960C2 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN SECOND TRIMESTER OF PREGNANCY | 2014 |
|
RU2552931C1 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING SEVERE COMPLICATIONS OF PREECLAMPSIA | 2020 |
|
RU2741730C1 |
| METHOD OF PREDICTING PREECLAMPSIA THERAPY EFFICIENCY | 2011 |
|
RU2475753C1 |
| METHOD OF PREDICTING LATE TOXICOSIS IN PREGNANT COWS | 2023 |
|
RU2802503C1 |
| METHOD FOR PREDICTION OF RISK OF SEVERE NEONATAL NERVOUS SYSTEM INVOLVEMENT IN NEW-BORNS OF VARIOUS GESTATIONS | 2012 |
|
RU2528907C2 |
| METHOD FOR PREDICTING LIGHT-DEGREE GESTOSIS SINCE EARLY TERMS OF PREGNANCY | 2004 |
|
RU2265221C2 |
| METHOD FOR FORECASTING DEVELOPMENT OF PRE-ECLAMPSIA IN LATE PREGNANCY | 2018 |
|
RU2691114C1 |
| METHOD FOR PREDICTING GESTOSIS IN PREGNANT WOMEN WITH THE RISK FOR MISCARRIAGE OF INFECTIOUS GENESIS | 2003 |
|
RU2246255C2 |
